AIDS Drug Assistance Programs: Highlighting inequities in human immunodeficiency virus-infection health care in the United States
AIDS Drug Assistance Programs: Highlighting inequities in human immunodeficiency virus-infection health care in the United States
复制标题
DOI：
10.1086/341903
复制
发表时间：
2002-09-01
影响因子：
11.8
通讯作者：
Freedberg, KA
中科院分区：
文献类型：
--
作者：
Walensky, RP;Paltiel, AD;Freedberg, KA
艾滋病药物援助计划（ADAPs）成立于1987年，在美国支付与人类免疫缺陷病毒（HIV）相关的药物，并帮助为没有私人健康保险的没有资格享受医疗补助的HIV感染患者提供处方。由于艾滋病毒护理已从住院病人转移到门诊病人，而且由于抗逆转录病毒疗法更有效，病人寿命更长，药物费用增加了，适应方案越来越多地在紧急措施下运作，覆盖范围有限，资格也有限制。由于这些项目在州一级运作，资源分配给有需要的人的不平等是显而易见的，而且似乎导致了仅仅基于患者居住地的疾病结果的差异。成本效益分析将为有效和公平地分配亚太发展援助计划资源提供更明智的基础，从而形成标准化的国家结构。
The AIDS Drug Assistance Programs (ADAPs) were founded in 1987 to pay for human immunodeficiency virus (HIV)-related medications in the United States and to help provide prescriptions for HIV-infected patients ineligible for Medicaid who have no private health insurance. As HIV care has shifted from the inpatient to the outpatient arena and as patients live longer because of more-effective antiretroviral therapy, medication costs have increased, and ADAPs have increasingly been operating under emergency measures, with coverage limitations and eligibility restrictions. Because these programs operate at the state level, inequalities in resource distribution to those in need are manifest and appear to contribute to differences in disease outcomes that are based solely on patients' place of residence. Cost-effectiveness analysis would offer a more informed basis for distribution of ADAP resources in an efficient and equitable manner, leading to a standardized national structure.